Pharmacokinetic Evaluation of Intranasal Nalmefene Using Three Dosing Regimens
Primary Purpose
Opioid Overdose
Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Nalmefene Hydrochloride
Sponsored by
About this trial
This is an interventional basic science trial for Opioid Overdose focused on measuring Pharmacokinetics
Eligibility Criteria
Inclusion Criteria:
- Male or female aged 18 to 55 years inclusive
- BMI ranging from 18 to 30 kg/m2, inclusive
- Adequate venous access
- Subjects must be non-smokers
Exclusion Criteria:
- History of clinically significant disease
- Significant trauma injury, major surgery, open biopsy within 30 days prior to screening
- Following an abnormal diet 4 weeks prior to screening
- Use of over the counter medications, dietary supplements, herbal products, vitamins or opioid analgesics 14 days before intervention
- Use of enzyme altering drugs 30 days before intervention
- Use of nasal products 28 days before intervention and throughout the study
- Previous or current opioid, alcohol, or other drug dependence
- Donated or received blood 30 days before intervention
- Women who are pregnant or breastfeeding at screening
- Women of childbearing potential unless surgically sterile or use effective contraception
- Male subjects of childbearing potential that do not agree to use effective contraception
- Male subjects who plan to donate sperm or have female partner(s) who are pregnant, lactating or planning to attempt to become pregnant
- Current or recent upper respiratory tract infection
- Allergic to nalmefene
Sites / Locations
- WorldWide Clinical Trials
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Experimental
Arm Label
Intranasal Nalmefene 1 spray in 1 nostril
Intranasal Nalmefene 2 sprays in 1 nostril
Intranasal Nalmefene 1 spray in each nostril
Arm Description
Nalmefene Hydrochloride nasal spray, 3mg, 1 spray in 1 nostril
Nalmefene Hydrochloride nasal spray, 6mg, 2 sprays in 1 nostril
Nalmefene Hydrochloride nasal spray, 6mg, 1 spray in each nostril
Outcomes
Primary Outcome Measures
Maximum plasma concentration (Cmax)
Maximum concentration of plasma nalmefene comparing 1 dose of IN in one nostril to 2 doses of IN in 1 nostril to 1 dose of IN in each nostril
Time to maximum plasma concentration (Tmax)
Time to maximum concentration of plasma nalmefene comparing 1 dose of IN in one nostril to 2 doses of IN in 1 nostril to 1 dose of IN in each nostril
Area under the curve (AUC)
Area under the curve of plasma nalmefene comparing 1 dose of IN in one nostril to 2 doses of IN in 1 nostril to 1 dose of IN in each nostril
Half-life (t1/2)
Half life of plasma nalmefene comparing 1 dose of IN in one nostril to 2 doses of IN in 1 nostril to 1 dose of IN in each nostril
Secondary Outcome Measures
Full Information
NCT ID
NCT05219669
First Posted
January 21, 2022
Last Updated
December 8, 2022
Sponsor
Opiant Pharmaceuticals Inc
1. Study Identification
Unique Protocol Identification Number
NCT05219669
Brief Title
Pharmacokinetic Evaluation of Intranasal Nalmefene Using Three Dosing Regimens
Official Title
An Open-Label, Three-Period, Three-Treatment, Six-Sequence, Randomized Crossover Study of the Pharmacokinetics of Intranasal Nalmefene in Healthy Volunteers Using Three Dosing Regimens
Study Type
Interventional
2. Study Status
Record Verification Date
December 2022
Overall Recruitment Status
Completed
Study Start Date
September 1, 2021 (Actual)
Primary Completion Date
November 19, 2021 (Actual)
Study Completion Date
November 22, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Opiant Pharmaceuticals Inc
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study is to compare the pharmacokinetics (how the body absorbs, breaks down and eliminates drug from your body) of nalmefene when given as a single dose intranasally (IN;into the nose), as a single dose in each nostril and as two doses in one nostrils; and to evaluate the safety and tolerability of nalmefene IN.
Detailed Description
Open-label, randomized, 3-period, 3-treatment, 6-sequence, ranodmised crossover study in 24 healthy volunteers. Subjects will be assigned to each of the 6 possible sequences. Each subject will receive 3 intranasal (IN) nalmefene doses:
3mg IN dose (one 0.1mL spray of a 30mg/mL solution in one nostril)
6mg IN dose (one 0.1mL spray of a 30mg/mL solution in each nostril)
6mg IN dose (two 0.1mL sprays of a 30mg/mL solution in one nostril) There will be a 6 day washout period between doses. Screening can occur up to 28 days before admission, subjects will then stay in the inpatient facility for 16 days to complete the treatment phase of the study and will be discharged following completion of the discharge procedures at the end of the last period. Subjects will be called 3 to 5 days after discharge to inquire concerning Adverse Events (AEs) and concomitant medications since discharge.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Opioid Overdose
Keywords
Pharmacokinetics
7. Study Design
Primary Purpose
Basic Science
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
24 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Intranasal Nalmefene 1 spray in 1 nostril
Arm Type
Experimental
Arm Description
Nalmefene Hydrochloride nasal spray, 3mg, 1 spray in 1 nostril
Arm Title
Intranasal Nalmefene 2 sprays in 1 nostril
Arm Type
Experimental
Arm Description
Nalmefene Hydrochloride nasal spray, 6mg, 2 sprays in 1 nostril
Arm Title
Intranasal Nalmefene 1 spray in each nostril
Arm Type
Experimental
Arm Description
Nalmefene Hydrochloride nasal spray, 6mg, 1 spray in each nostril
Intervention Type
Drug
Intervention Name(s)
Nalmefene Hydrochloride
Intervention Description
3mg nasal spray
Primary Outcome Measure Information:
Title
Maximum plasma concentration (Cmax)
Description
Maximum concentration of plasma nalmefene comparing 1 dose of IN in one nostril to 2 doses of IN in 1 nostril to 1 dose of IN in each nostril
Time Frame
48 hours
Title
Time to maximum plasma concentration (Tmax)
Description
Time to maximum concentration of plasma nalmefene comparing 1 dose of IN in one nostril to 2 doses of IN in 1 nostril to 1 dose of IN in each nostril
Time Frame
48 hours
Title
Area under the curve (AUC)
Description
Area under the curve of plasma nalmefene comparing 1 dose of IN in one nostril to 2 doses of IN in 1 nostril to 1 dose of IN in each nostril
Time Frame
48 hours
Title
Half-life (t1/2)
Description
Half life of plasma nalmefene comparing 1 dose of IN in one nostril to 2 doses of IN in 1 nostril to 1 dose of IN in each nostril
Time Frame
48 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Male or female aged 18 to 55 years inclusive
BMI ranging from 18 to 30 kg/m2, inclusive
Adequate venous access
Subjects must be non-smokers
Exclusion Criteria:
History of clinically significant disease
Significant trauma injury, major surgery, open biopsy within 30 days prior to screening
Following an abnormal diet 4 weeks prior to screening
Use of over the counter medications, dietary supplements, herbal products, vitamins or opioid analgesics 14 days before intervention
Use of enzyme altering drugs 30 days before intervention
Use of nasal products 28 days before intervention and throughout the study
Previous or current opioid, alcohol, or other drug dependence
Donated or received blood 30 days before intervention
Women who are pregnant or breastfeeding at screening
Women of childbearing potential unless surgically sterile or use effective contraception
Male subjects of childbearing potential that do not agree to use effective contraception
Male subjects who plan to donate sperm or have female partner(s) who are pregnant, lactating or planning to attempt to become pregnant
Current or recent upper respiratory tract infection
Allergic to nalmefene
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ingela Danielsson, MD
Organizational Affiliation
Worldwide Clinical Trials
Official's Role
Principal Investigator
Facility Information:
Facility Name
WorldWide Clinical Trials
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78217
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Pharmacokinetic Evaluation of Intranasal Nalmefene Using Three Dosing Regimens
We'll reach out to this number within 24 hrs